



**BlueCross BlueShield
of Alabama**

See National Coverage Determination (NCD) for Treatment of ACTINIC KERATOSIS (250.4) for coverage criteria of actinic keratosis.

Name of Blue Advantage Policy:
Chemical Peels

Policy #: 052
Category: Surgical

Latest Review Date: December 2019
Policy Grade: A

BACKGROUND:

Blue Advantage medical policy does not conflict with Local Coverage Determinations (LCDs), Local Medical Review Policies (LMRPs) or National Coverage Determinations (NCDs) or with coverage provisions in Medicare manuals, instructions or operational policy letters. In order to be covered by Blue Advantage the service shall be reasonable and necessary under Title XVIII of the Social Security Act, Section 1862(a)(1)(A). The service is considered reasonable and necessary if it is determined that the service is:

- 1. Safe and effective;*
- 2. Not experimental or investigational*;*
- 3. Appropriate, including duration and frequency that is considered appropriate for the service, in terms of whether it is:*
 - Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient's condition or to improve the function of a malformed body member;*
 - Furnished in a setting appropriate to the patient's medical needs and condition;*
 - Ordered and furnished by qualified personnel;*
 - One that meets, but does not exceed, the patient's medical need; and*
 - At least as beneficial as an existing and available medically appropriate alternative.*

In accordance with Title XVIII of the Social Security Act, Section 1862 (a)(10) cosmetic surgery or expenses incurred in connection with such surgery is not covered except as required for the prompt repair of accidental injury or for improvement of the functioning of a malformed body member.

Routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000 which meet the requirements of the Clinical Trials NCD are considered reasonable and necessary by Medicare. Providers should bill **Original Medicare for covered services that are related to **clinical trials** that meet Medicare requirements (Refer to Medicare National Coverage Determinations Manual, Chapter 1, Section 310 and Medicare Claims Processing Manual Chapter 32, Sections 69.0-69.11).*

POLICY:

Effective for dates of service on or after September 15, 2016:

Blue Advantage will treat dermal chemical peels as a covered benefit when used to treat extensive actinic keratosis (greater than 10 lesions) when photodynamic therapy (PDT) with topical 5-aminolevulinic acid is not a treatment option due to the presence of hyperkeratotic lesions and the patient is unable to tolerate treatment with topical 5-FU.

Blue Advantage will treat epidermal chemical peels as a covered benefit when used to treat active comedonal acne that has failed a trial of topical and/or oral antibiotic acne therapy. In this setting, epidermal chemical peels with 50-70% alpha-hydroxy acids are used as a comedolytic therapy.

- **Up to 8 epidermal (superficial) peels may be considered as a covered benefit** for treatment of comedonal acne.
- Pre-procedural photos must document the presence of active comedonal acne and be submitted for review along with the clinical documentation. Each photo should be labeled with the patient name, date and procedure to be performed.
- Photos should include the following:
 - Full-face front
 - Right and left oblique
 - Close-up of regional area
- The active ingredient and strength should be documented for each treatment session as well as any changes noted from previous treatment.

Blue Advantage will treat epidermal chemical peels with 50 - 70% alpha hydroxy acids as a first-line treatment of active acne as a non-covered benefit.

Blue Advantage will treat subsequent epidermal (superficial) peels (i.e., >8) for treatment of active comedonal acne as a covered benefit with submission of supportive clinical documentation, including pre- and post-procedural photos of previous treatments showing improvement of condition.

- Each photo should be labeled with the patient name, date and procedure to be performed.
- Photos should include the following:
 - Full-face front
 - Right and left oblique
 - Close-up of regional area
- The active ingredient and strength should be documented for each treatment session as well as any changes noted from previous treatment.

Blue Advantage will treat chemical peels performed for photoaged skin, wrinkles or acne scarring as a non-covered benefit and as cosmetic.

Effective for dates of service on or after October 18, 2011 and prior to September 15, 2016:

Blue Advantage will treat dermal chemical peels may be as a covered benefit when used to treat extensive actinic keratosis (greater than 10 lesions) when photodynamic therapy

(PDT) with topical 5-aminolevulinic acid is not a treatment option due to the presence of hyperkeratotic lesions and the patient is unable to tolerate treatment with topical 5-FU.

Blue Advantage will treat **epidermal chemical peels** as a **covered** benefit when used to treat **active acne**.

Blue Advantage will treat **chemical peels** performed for photoaged skin, wrinkles or acne scarring as a **non-covered** benefit and as **cosmetic**.

See National Coverage Determination (NCD) for Treatment of ACTINIC KERATOSIS (250.4) for coverage criteria of actinic keratosis.

Blue Advantage does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Advantage administers benefits based on the members' contract and medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.

DESCRIPTION OF PROCEDURE OR SERVICE:

A chemical peel refers to a controlled removal of varying layers of the epidermis and superficial dermis with the use of an agent such as phenol or trichloroacetic acid (TCA). The most common indication for chemical peeling is as a treatment of photoaged skin, i.e. correction of pigmentation abnormalities, solar elastosis, and wrinkles. However, chemical peeling has also been used as a treatment for multiple actinic keratosis, active acne, and acne scarring.

Chemical Peels

Chemical peels involve a controlled partial-thickness burn of the epidermis and the outer dermis. When skin is regenerated, a 2-3mm band of dense, compact collagen is formed between the epidermis and the damaged layers of the dermis, resulting in the ablation of fine wrinkles and a reduction in pigmentation. These changes can be long term, lasting up to 15 to 20 years and may be permanent in some patients. Potential local complications include scarring, infection, hypopigmentation, activation of herpes simplex and toxic shock syndrome.

Types of Peels

Chemical peels are often categorized according to the depth of the peel: categories include superficial medium-depth and deep chemical peels. The precise depth of the peel depends on the concentration of the agent used, duration of the application and the number of applications. Possible indications for each type of peel and common chemicals used, as described in 2005 by Cummings et al, is as follows.

Superficial Peels

Superficial peels (epidermal peels) affect the epidermis and the interface of the dermis-epidermis. This depth is considered appropriate for treating mild photoaging, melasma, comedonal acne and post-inflammatory erythema. Common chemical agents used for superficial peels include low concentrations of glycolic acid, 10-20% trichloroacetic acid (TCA), Jessner's solution (a mixture of resorcinol, salicylic acid, lactic acid and ethanol), tretinoin, 5-fluorouracil (5-FU) and salicylic acid. As part of the treatment process, superficial peels generally cause mild erythema and desquamation, and the healing time ranges from 1 to 4 days, depending on the strength of the chemical agent. With superficial peels, patients often undergo multiple sessions; generally a total of six to eight peels performed weekly or every other week.

Medium-Depth Peels

Medium-depth peels (dermal peels) extend through the epidermis to the papillary dermis. These are used for moderate photoaging, actinic keratoses and mild acne scarring. In the past, 50% TCA was a common chemical agent for medium-depth peels but its use has decreased due to a high rate of complications such as pigmentary changes and scarring. Currently, the most frequently used agent is a combination of 35% TCA with Jessner's solution or 70% glycolic acid. Phenol 88% alone is also used for medium-depth peels. The healing process involves mild to moderate edema, followed by the appearance of new, erythematous epithelium. Patients are advised to wait at least 3 months before resuming skin care services, such as superficial chemical peels, and repeat medium-depth chemical peels should not be performed for at least 1 year.

Deep Peels

Deep chemical peels (another type of dermal peel) penetrate the mid-reticular dermis and are used for patients with severe photodamage. The most common chemical agent used is Baker's solution (which consists of 88% phenol, 8 drops of Septisol, 3 drops of croton oil, and 2 mL of distilled water). The same depth can be achieved using 50% or greater TCA peels; however the latter has a higher risk of scarring and pigmentation problems. Phenol is cardiotoxic and patients must be screened for cardiac arrhythmias or medical that are could potentially precipitate an arrhythmia. Phenol can also have renal and hepatic toxicities.

The likelihood and potential severity of adverse effects increases as the strength of the chemicals and depth of peels increases. With deep chemical peels, there is the potential for long-term pigmentary disturbances (i.e., areas of hypopigmentation) and selection of patients willing to always wear makeup is advised. Moreover, chemical peels reduce melanin protection so patients must use protective sunscreen for 9 to 12 months after a medium- to deep-facial peel.

Chemical peels are a potential treatment option for actinic keratoses and moderate-to-severe acne. Actinic keratoses are common skin lesions associated with extended exposure to the sun, with an estimated prevalence in the United States of 11% to 26%. They are generally considered to be a precursor of squamous cell carcinoma (SCC). The risk of progression to invasive SCC is unclear, but estimates vary from 0.1% to 20%.³ For patients with multiple actinic keratoses, risk of developing invasive squamous cell carcinoma is estimated as being between 0.15% and 80%. Treatment options include watchful waiting, medication treatment, cryosurgery, surgical resection.

Acne vulgaris is the most common skin condition among adolescents, affecting an estimated 80% of 13- to 18-year olds. Acne, particularly moderate-to-severe manifestations, can cause psychologic distress including low self-esteem, depression, and anxiety. There are a variety of oral and topical treatments for acne.

KEY POINTS:

This policy has been updated regularly with searches of the MEDLINE database. Most recently, the literature was reviewed through October 14, 2019.

Summary of Evidence

For individuals who have actinic keratoses who receive chemical peels, the evidence includes a nonrandomized split-face study and case series. Relevant outcomes are symptoms, morbid events, quality of life, and treatment-related morbidity. The split-face study found similar outcomes after a single chemical peel or 3 weeks of treatment with 5% fluorouracil cream in 15 patients. A case series found high response rates and low recurrence rates at 1 year in patients with actinic keratoses treated with phenol peels. Additional controlled studies, preferably randomized, are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have moderate-to-severe active acne who receive chemical peels, the evidence includes randomized controlled trials (RCTs). Relevant outcomes are symptoms, morbid events, quality of life, and treatment-related morbidity. One small randomized trial was placebo-controlled; it found greater efficacy with active treatment than with placebo. Several RCTs comparing chemical peel agents in patients with acne generally reported comparable improvements with the various types of chemical peels studied. However, no studies were identified comparing chemical peel agents with conventional acne treatment. The evidence is insufficient to determine the effects of the technology on health outcomes.

Practice Guidelines and Position Statements

British Association of Dermatologists

In 2007, British Association of Dermatologists published a guideline on the management of actinic keratoses. Chemical peels were given a ‘C, III’ rating, meaning that there is “poor evidence to support the use of the procedure” and the evidence consists of “opinions of respected authorities based on clinical experience, descriptive studies or reports of expert committees.”

American Academy of Dermatology

In 2007, American Academy of Dermatology published a guideline on management of acne vulgaris which included the statement, “There is limited evidence regarding the benefit of physical modalities including glycolic acid peels and salicylic acid peels.”

American Society for Dermatologic Surgery

The American Society for Dermatologic Surgery published recommendations in 2017 on the use of several skin treatments following a course of isotretinoin, a treatment for severe cystic acne. Previously, a number of cosmetic skin treatments, including chemical peels, were discouraged for 6 months after the use of isotretinoin. These 2017 guidelines evaluated various treatments in

the context of scarring and found that superficial chemical peels were safe as a treatment either concurrent with isotretinoin or within 6 months of its discontinuation. The lack of data on medium or deep chemical peels did not permit the Society to make a recommendation on those treatments.

U.S. Preventive Services Task Force Recommendations

Not Applicable.

KEY WORDS:

Chemical peel, skin peel, actinic keratoses, active acne, premalignant skin lesions, comedonal acne, epidermal peel, superficial peel, alpha hydroxy acids, comedolytic therapy

APPROVED BY GOVERNING BODIES:

FDA clearance or approval may not be relevant for the chemical agents used in peeling because they are prepared in-office, may have pre-dated FDA approval and/or may be considered cosmetic ingredients.

BENEFIT APPLICATION:

Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable.

ITS: Home Policy provisions apply

FEP: Special benefit consideration may apply. Refer to member's benefit plan. FEP does not consider investigational if FDA approved and will be reviewed for medical necessity.

CURRENT CODING:

CPT code:	15788	Chemical peel, facial, epidermal
	15789	Chemical peel, facial, dermal
	15792	Chemical peel, nonfacial, epidermal
	15793	Chemical peel, nonfacial, dermal

REFERENCES:

1. Abdel Meguid AM, Elaziz Ahmed Attallah DA, Omar H. Trichloroacetic acid versus salicylic acid in the treatment of acne vulgaris in dark-skinned patients. *Dermatol Surg*. Dec 2015;41(12):1398-1404.
2. Bae BG, Park CO, Shin H et al. Salicylic acid peels versus Jessner's solution for acne vulgaris: a comparative study. *Dermatol Surg* 2013; 39(2):248-253.
3. Brodland DG and Roenigk RK. Trichloroacetic acid chemexfoliation (chemical peel) for extensive premalignant actinic damage of the face and scalp. *Mayo Clin Proc*, September 1988; 63(9): 887-896.

4. Costa C, Scalvenzi M, Ayala F, et al. How to treat actinic keratosis? An update. *J Dermatol Case Rep.* Jun 30 2015;9(2):29-35.
5. Cummings CW, Haughey BH, Thomas JR, et al. *Otolaryngology: Head and Neck Surgery*, 4th edition, 2005. Mosby, Chapter 29, pp. 700-711.
6. Dayal S, Amrani A, Sahu P, et al. Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. *J Cosmet Dermatol.* Mar 2017;16(1):43-51.
7. de Berker D, McGregor JM and Hughes Br. British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses. *Br J Dermatol*, February 2007; 156(2): 222-230.
8. Dinehart SM. Actinic keratoses: scientific evaluation and public health implications. The treatment of actinic keratoses, *J Am Acad of Dermotol* 2000; 42:1.
9. Feldman SR, Fleishcer AB, Williford PM, and Jorizzo JL. Destructive procedures are the standard of care for treatment of actinic keratoses, *J Am Acad of Dermotol* 1999; 40:1.
10. Habif TP. *Clinical Dermatology 5th Edition*. Philadelphia, PA: Mosby/Elsevier; 2010.
11. Ilknur T, Demirtasoglu M, Bicak MU et al. Glycolic acid peels versus amino fruit acid peels for acne. *J Cosmet Laser Ther* 2010; 12(5):242-245.
12. Jerant A.F. Early detection and treatment of skin cancer, *Am Family Phys* 2000; 62: 5.
13. Kaminaka C, Uede M, Matsunaka H et al. Clinical evaluation of glycolic acid chemical peeling in patients with acne vulgaris: a randomized, double-blind, placebo-controlled, split-face comparative study. *Dermatol Surg* 2014; 40(3):314-322.
14. Kaminaka C, Yamamoto Y, Yonei N, et al. Phenol peels as a novel therapeutic approach for actinic keratosis and Bowen disease: Prospective pilot trial with assessment of clinical, histologic and immunohistochemical correlations. *J Am Acad Dermatol*, April 2009; 60(4): 615-625.
15. Kessler E, Flanagan K, Chia C et al. Comparison of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. *Dermatol Surg* 2008; 34(1):45-50; discussion 51.
16. Lawrence N. New and emerging treatments for photoaging, *Dermatologic Clinics* 2000; 18:1.
17. Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. *Arch Dermatol.* Feb 1995;131(2):176-181.
18. Levesque A, Hamzavi I, Seite S et al. Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. *J Cosmet Dermatol* 2011; 10(3):174-178.
19. Lincolin EA. Sun-induced skin changes, *Primary Care; Clinics in Office Practice* 2000; 27:2.
20. Morganroth GS and Leffell DJ. Nonexcisional treatment of benign and premalignant cutaneous lesions. *Clin Plast Surg*, January 1993; 20(1): 91-104.
21. Padilla RS, Sebastian S, Jiang Z, et al. Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. *Arch Dermatol.* Mar 2010;146(3):288-293.
22. Purdy S, de Berker D. Acne vulgaris. *BMJ Clin Evid.* Jan 05 2011;2011.
23. Strauss JS, Krowchuk DP, Leyden JJ et al; American Academy of Dermatology/American Academy of Dermatology Association. Guidelines of care for acne vulgaris management. *J Am Acad Dermatol* 2007; 56(4):651-663.

24. Van Scott EJ and Yu RJ. Alpha hydroxy acids: Procedures for use in clinical practice. *Cutis*, March 1989; 43(3): 222-228.
25. Waldman A, Bolotin D, Arndt KA, et al. ASDS Guidelines Task Force: consensus recommendations regarding the safety of lasers, dermabrasion, chemical peels, energy devices, and skin surgery during and after isotretinoin use. *Dermatol Surg.* Oct 2017;43(10):1249-1262.
26. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. *J Am Acad Dermatol.* May 2016;74(5):945-973 e933

POLICY HISTORY:

Adopted for Blue Advantage, March 2005

Available for comment May 1-June 14, 2005

Medical Policy Group, July 2006

Medical Policy Group, July 2008

Medical Policy Group, July 2010

Available for comment September 2 through October 17, 2011

Medical Policy Group, July 2012

Medical Policy Group, July 2013

Medical Policy Group, July 2014

Medical Policy Group, July 2015

Medical Policy Group, July 2016

Available for comment August 1 through September 14, 2016

Medical Policy Group, December 2016

Medical Policy Group, December 2017

Medical Policy Group, December 2019

This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member's plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield's administration of plan contracts.